REPLICor to present at TIDES 2006
Laval, Quebec – April 28, 2006 – REPLICor announced today that it will be a presenter at TIDES 2006 in Carlsbad, CA. This poster presentation will be given by Dr Andrew Vaillant, CSO on May 1st, 2006.
“We are pleased to present the first complete disclosure of REPLICor’s novel nucleic-acid based technology and to report REPLICor’s latest developments in applying this technology as an antiviral therapy and in several other therapeutic areas” commented Dr Vaillant. “TIDES is the premiere conference in the World for nucleic-acid based technologies and we are proud to be one of the presenting companies” he added.
About TIDES 2006
TIDES is a annual meeting for the oligonucleotide and peptide industries. It is heavily attended not only by small and mid-range companies having peptide and or nucleic acid-based technology platforms but also by the Pharma industry due to the innovative approaches nucleic-acid and peptide based technologies (such as antisense and aptamer technologies) bring to undruggable targets or difficult to treat diseases.
About REPLICor
REPLICor Inc. is a biopharmaceutical company developing novel broad-spectrum antiviral drugs. Its lead compound, REP 9, is active against 12 viral families including influenza, hepatitis B and C, HIV, RSV and herpes. The company’s business strategy is to enter into an alliance with a major pharmaceutical company to further develop and market its technology.
For more information:
Andrew Vaillant PhD, CSO
REPLICor Inc.
450 688 6068